A residual solvent result is useful only when it answers the purchasing question: does this tested sample provide adequate evidence for the lot, specification and intended use being reviewed? A green “pass” badge cannot answer that alone.
For buyers evaluating CBD isolate, the practical work is to connect each reported solvent to an identifiable sample, a suitable test and an applicable acceptance criterion. This guide offers a proposed procurement worksheet, not a description of Vetrux's internal procedures or a universal release standard. It does not cover extraction, purification or treatment decisions.
The cover image is an AI-generated laboratory illustration, not a photograph of Vetrux equipment or a test result.
Start with the acceptance basis, not a limit copied online
Record the destination market, product category, intended use and agreed purchase specification before interpreting a pass/fail result. Ask the responsible quality or regulatory reviewer to identify which requirements apply. A supplier's default laboratory limit may not be the criterion your project needs.
ICH Q3C concerns residual solvents in pharmaceuticals; it is not a blanket approval framework for every CBD application. As checked on September 12, 2026, EMA lists Q3C(R9) as the current effective version, effective April 29, 2024. Its separate 2026 annex revision remains labelled “Draft: consultation closed.” Do not treat that draft as an adopted requirement. EMA's Q3C version record identifies both statuses.
If a supplier cites ICH, ask which provision supports the proposed specification and why it is appropriate to your intended use. Keep that explanation with the review instead of recording only “ICH compliant.”
Confirm what was sampled and what the panel covers
Obtain the complete report, including its legend and any amended pages. Match the material description, supplier lot, laboratory sample identifier and report number. Record sampling, receipt, testing and issue dates separately where available. If the supplier and laboratory use different identifiers, request the document connecting them.
Then compare the named solvent panel with the supplier's documented process-related solvent information. Ask about an unexplained omission; a solvent absent from the panel has no reported result. A generic cannabinoid purity report is not a substitute for the missing solvent section. Our COA reading guide provides broader report context.
For a useful real-world distinction, FSA's 2022–23 consumer-product survey used headspace GC-MS for residual solvents but explicitly identified that methodology as outside ISO 17025 accreditation. The report therefore supports asking about the specific test's status, not inferring coverage from a laboratory logo. It does not establish the quality of any supplier's isolate. See FSA's methods section.
Read “ND,” reporting limits and units together
Ask the laboratory to define every abbreviation. Does “ND” refer to a detection limit, a quantification limit or another reporting convention? Request the relevant threshold for each solvent, not an assumed panel-wide value.
Detection and quantification answer different questions. ICH Q2(R2) distinguishes detecting a small amount from measuring it quantitatively with suitable precision and accuracy. These are analytical concepts, not CBD acceptance limits; the guideline itself addresses pharmaceutical analytical procedures. See the glossary in FDA's Q2(R2) guidance.
For procurement purposes, do not translate “below the reporting limit” into “zero.” If that reporting limit is higher than the acceptance criterion, the entry alone cannot show that the criterion is met. Ask for an appropriate test or documented technical resolution.
Copy units and reporting basis exactly. Have the laboratory clarify an ambiguous “ppm,” and do not directly compare mass-based and volume-based results without an agreed conversion basis. Keep any conversion beside the original result so another reviewer can reproduce it.
Use a worksheet that exposes missing evidence
The following is an original review aid. Create one record per supplier lot, with separate rows for each required solvent. Leave unknown fields marked “unconfirmed” rather than treating blanks as passes.
Scroll horizontally to view the full table.
| Review field | Evidence to record | Action if unresolved |
|---|---|---|
| Lot and sample link | Supplier lot, lab sample ID, report revision | Request the identity cross-reference |
| Solvent coverage | Named analytes and rationale for the panel | Ask about omissions or exclusions |
| Analytical method | Method identifier, matrix and test scope | Request suitability evidence for isolate |
| Result interpretation | Value or qualifier, units and reporting threshold | Obtain the laboratory's legend or clarification |
| Acceptance criterion | Limit, source, version and intended-use rationale | Refer to the responsible quality reviewer |
| Review outcome | Decision, reviewer, date and open items | Keep affected approval pending |
Add the supplier's response and document filename directly to the relevant row. This makes a follow-up such as “please clarify the report” more precise: “please define ND for the named analyte and confirm its reporting threshold in the stated units.”
Resolve gaps without losing the original record
Distinguish an incomplete report from a reported result that does not meet the agreed criterion. Missing units may require a corrected report; an unsuitable reporting threshold may require further analysis. Neither issue should disappear because a replacement PDF has a more reassuring summary.
Retain the original report, the question sent, the supplier or laboratory response and any amended version. For conflicting results, ask quality staff to assess sample identity, method differences and the proposed investigation before accepting a retest. Do not select whichever number is lower.
Use the worksheet again when a supplier changes its site, process-related solvent information or analytical method. The raw-material change-control guide explains how to connect that review with the approved material baseline.
When contacting Vetrux, include your intended use, destination market and required solvent panel, and ask which lot-specific evidence is available. A clearly scoped request makes it easier to identify what the documents establish, what remains uncertain and who must resolve it before purchase approval.
About the publisher
VETRUX Technical Content Team
CBD raw-material and sourcing context
VETRUX publishes practical material-handling, documentation, and supplier-qualification guidance from the perspective of a CBD raw-material supplier in Chuxiong, Yunnan.
Learn more about VETRUX →
